Ozempic for weight loss explained: what the FDA label covers, what off-label use means, Ozempic vs Wegovy, trial numbers, insurance, dated prices and questions to ask.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- Ozempic is FDA approved only for adults with type 2 diabetes (blood sugar, heart and kidney risk); weight management is not on its label.[1]
- Prescribers may use an approved drug off label when they judge it appropriate, but the FDA has not found it safe and effective for that use.[3]
- In Ozempic's 30-week diabetes trial, average weight change was -4.7 kg on 1 mg vs -1.2 kg on placebo; in STEP 1, Wegovy 2.4 mg produced -14.9% vs -2.4% in adults without diabetes.[4]
- Medicare's temporary GLP-1 Bridge for weight (July 2026 to December 2027) includes Wegovy, Zepbound KwikPen and Foundayo, not Ozempic.[8]
- Self-pay at NovoCare Pharmacy (checked 2026-10-06): Ozempic pens $349-$499 a month, Wegovy pens $349-$399, Wegovy tablets $149-$299.[7]
In short: Ozempic is not FDA approved for weight loss. Its label covers adults with type 2 diabetes: blood sugar control, lowering the risk of heart attack and stroke in people with heart disease, and protecting the kidneys in people with chronic kidney disease. People do lose some weight on it, and a prescriber may legally use it “off label”, but the FDA has not reviewed Ozempic as a weight treatment. The same medicine, semaglutide, is FDA approved for weight management under the brand name Wegovy, as a weekly shot and a daily pill (labels checked on 2026-10-06).
This guide explains what “off label” means, what the Ozempic trials showed about weight, how Ozempic and Wegovy differ, what insurance usually does with each, and what to ask before any decision. It is information only. InstaTuck does not sell or prescribe any medicine, and nothing here replaces an evaluation by a licensed clinician who knows your health history. Please do your own research, talk with a doctor and get evaluated before starting, stopping or switching any treatment.
Ozempic and weight at a glance
- 3uses on the Ozempic label, all for adults with type 2 diabetes; weight management is not one of themDailyMed, Ozempic label
- 4.7 kgaverage weight change with Ozempic 1 mg after 30 weeks in a diabetes trial (placebo: 1.2 kg)DailyMed, Ozempic label
- 14.9%average weight loss with Wegovy 2.4 mg at 68 weeks in adults without diabetes (STEP 1)NEJM 2021
Checked on October 6, 2026
What Ozempic is approved for
Ozempic is Novo Nordisk’s once-weekly semaglutide injection. Its current FDA label (DailyMed, revised May 2026) lists three uses, each in adults with type 2 diabetes and each alongside diet and exercise:
- to improve blood sugar (glycemic) control;
- to reduce the risk of major cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in adults who also have established cardiovascular disease;
- to reduce the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in adults who also have chronic kidney disease.
Chronic weight management is not on that list. The Ozempic page on InstaTuck covers the drug itself, its side effects and its approved uses in depth; this page is about the narrower question of using it for weight. If you want the weight-management medicine that contains the same ingredient, that is Wegovy, and our Ozempic vs Wegovy comparison lines the two up side by side.
What “off label” means
The FDA approves a medicine for specific uses, in specific people, based on the evidence the company submitted. Using an approved medicine for a different purpose is called unapproved or “off-label” use. According to the FDA, once a drug is approved, healthcare providers generally may prescribe it for an unapproved use when they judge it medically appropriate for their patient. The FDA also reminds patients that, for an off-label use, it has not determined that the drug is safe and effective for that use.
Off label is not the same as illegal, and it is not the same as “compounded” or “gray market”. It simply means the use sits outside what the label covers, so the prescriber and patient carry more of the judgment. That matters for weight, because a separate semaglutide product, Wegovy, was studied and approved for exactly that purpose, with doses and devices designed for it.
How semaglutide affects weight
Semaglutide acts like GLP-1, a hormone released by the gut after eating. The Ozempic label says semaglutide lowers fasting and after-meal blood sugar and reduces body weight; the Wegovy label adds that it lowers weight with greater fat mass loss than lean mass loss and decreases calorie intake, effects that are likely mediated through appetite. Our semaglutide page explains the mechanism in more detail, and the GLP-1 medications guide covers the whole class.
What the Ozempic trials showed about weight
Ozempic’s clinical trials were designed to test blood sugar, not weight, but they measured weight along the way. In the 30-week monotherapy trial in the label (adults with type 2 diabetes whose blood sugar was not controlled with diet and exercise), average weight changed by -3.8 kg on 0.5 mg and -4.7 kg on 1 mg, compared with -1.2 kg on placebo. In a 56-week comparison with sitagliptin, the changes were -4.2 kg and -5.5 kg versus -1.7 kg. In a 40-week trial comparing 1 mg and 2 mg, average changes were -5.6 kg and -6.4 kg, a difference that was not statistically significant.
| Item | Value |
|---|---|
| Placebo | 1.2 kg |
| Ozempic 0.5 mg | 3.8 kg |
| Ozempic 1 mg | 4.7 kg |
Bars show kilograms lost on average from a starting weight of about 89-97 kg. Weight was a secondary measure; the trial was designed to test blood sugar.
Source: Ozempic prescribing information, section 14 (DailyMed, revised May 2026) (checked on October 6, 2026)
Those losses are real but smaller than in the Wegovy weight trials, for several reasons that cannot be untangled from the outside: the people studied had type 2 diabetes, the trials were shorter, the doses were lower, and the programs were built around blood sugar rather than weight.
What the Wegovy weight trials showed
Wegovy was tested specifically for weight. In STEP 1 (New England Journal of Medicine, 2021), 1,961 adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and without diabetes, took weekly semaglutide 2.4 mg or placebo for 68 weeks with lifestyle support. Average weight change was -14.9% with semaglutide and -2.4% with placebo (-15.3 kg vs -2.6 kg). 86.4% of people on semaglutide lost at least 5% of their weight, 69.1% at least 10% and 50.5% at least 15%, compared with 31.5%, 12.0% and 4.9% on placebo.
| Item | Semaglutide 2.4 mg (Wegovy) | Placebo |
|---|---|---|
| Lost 5% or more | 86.4% | 31.5% |
| Lost 10% or more | 69.1% | 12% |
| Lost 15% or more | 50.5% | 4.9% |
1,961 adults without diabetes, with lifestyle intervention in both groups.
Source: Wilding JPH et al., New England Journal of Medicine 2021 (STEP 1) (checked on October 6, 2026)
The trials of Ozempic and Wegovy are different studies in different people, so their numbers cannot be compared head to head. What they do show is that the product with the weight indication is the one that was studied for weight, at weight-management doses, for long enough to show the effect.
Ozempic vs Wegovy: same molecule, different products
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA-approved uses (general terms) | Adults with type 2 diabetes: blood sugar, heart risk, kidney risk | Weight reduction and long-term maintenance (adults; injection also teens 12+ with obesity); heart-risk reduction; MASH with liver fibrosis (injection, accelerated approval) |
| Forms | Weekly pens 0.25 mg to 2 mg; single-dose syringes | Weekly pens up to 2.4 mg and a 7.2 mg HD pen; daily tablets 1.5 to 25 mg |
| Label maximum (general) | 2 mg once weekly | 2.4 mg weekly (7.2 mg HD pen for some adults); 25 mg tablet daily |
| Boxed warning | Both: thyroid C-cell tumors in rodents; not for people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 | |
| Use together | The Wegovy label says not to use it with other semaglutide products or other GLP-1 receptor agonists | |
The pens are not interchangeable. Ozempic pens deliver diabetes doses, and the label’s step-up schedule (starting at 0.25 mg weekly for 4 weeks, then increasing at intervals of at least 4 weeks) is designed around blood sugar. Wegovy’s schedule steps up every 4 weeks to its own maintenance dose. Switching from one to the other is a prescriber’s decision.
Side effects and warnings are the same family
Using Ozempic for weight does not change its risks. In the Ozempic label’s placebo-controlled diabetes trials, nausea was reported by 15.8% (0.5 mg) and 20.3% (1 mg) of people versus 6.1% on placebo, and digestive side effects overall by 32.7% and 36.4% versus 15.3%. Most nausea, vomiting and diarrhea happened while the dose was being increased.
| Item | Ozempic 1 mg | Ozempic 0.5 mg | Placebo |
|---|---|---|---|
| Nausea | 20.3% | 15.8% | 6.1% |
| Vomiting | 9.2% | 5% | 2.3% |
| Diarrhea | 8.8% | 8.5% | 1.9% |
| Abdominal pain | 5.7% | 7.3% | 4.6% |
| Constipation | 3.1% | 5% | 1.5% |
Adults with type 2 diabetes; reactions reported in at least 5% of people on Ozempic.
Source: Ozempic prescribing information, Table 1 (DailyMed, revised May 2026) (checked on October 6, 2026)
The label’s warnings include thyroid C-cell tumors seen in rodents (boxed warning), acute pancreatitis, diabetic retinopathy complications, low blood sugar when combined with insulin or a sulfonylurea, acute kidney injury from fluid loss, severe digestive reactions, allergic reactions, acute gallbladder disease and pulmonary aspiration during general anesthesia or deep sedation. It also warns never to share an Ozempic pen between people, even with a new needle. The label advises stopping Ozempic at least 2 months before a planned pregnancy because semaglutide takes a long time to leave the body. For the full picture, see Ozempic side effects and our GLP-1 side effects guide.
Who should not use semaglutide
Both labels list the same contraindications: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a prior serious allergic reaction to semaglutide or any ingredient. People with a history of pancreatitis, gallbladder disease, diabetic eye disease, kidney problems or severe stomach-emptying problems, people planning pregnancy, and anyone taking insulin or a sulfonylurea need a careful conversation first. That is part of why an in-person or telehealth evaluation matters, whatever brand is involved.
Insurance: why coverage usually follows the label
Many insurance plans cover a medicine for the uses on its label and ask for prior authorization showing that use. A plan that covers Ozempic for type 2 diabetes may not cover it when there is no diabetes diagnosis, and coverage of weight-management medicines differs from plan to plan. Policies vary widely, so the only reliable answer comes from your own plan’s formulary and its prior-authorization rules. Our GLP-1 insurance coverage guide explains the questions to ask.
Medicare is a clear example of the label mattering. From July 1, 2026 to December 31, 2027, CMS runs a temporary Medicare GLP-1 Bridge for eligible Part D enrollees who use a GLP-1 to reduce excess weight and maintain weight reduction, with a $50 copay and prior authorization. The drugs on its list are Foundayo, Wegovy (injection and tablets) and the Zepbound KwikPen. Ozempic is not on the list; CMS notes that type 2 diabetes, moderate to severe sleep apnea and MASH are indications covered by regular Part D plans instead (checked on 2026-10-06).
Cost without insurance (checked on 2026-10-06)
Novo Nordisk sells both products at self-pay prices through NovoCare Pharmacy. New patients pay $199 a month for the first two fills of the 0.25 mg and 0.5 mg strengths of either Ozempic or Wegovy pens (offer through December 31, 2026). After that, Ozempic pens cost $349 a month for 0.25, 0.5 or 1 mg and $499 for 2 mg, and Wegovy pens cost $349 a month for 0.25 to 2.4 mg and $399 for the 7.2 mg HD pen. Wegovy tablets are $149 (1.5 mg), $199 (4 mg) and $299 (9 and 25 mg) a month. With commercial insurance that covers the medicine, a savings offer can bring the copay to as little as $25, with a maximum saving of $100 a month; government beneficiaries are excluded.
Compare totals for your situation with our GLP-1 cost comparison tool, and see Wegovy cost for coverage paths. Prices are set by the manufacturer and can change; always confirm the current price before you plan around it.
Counterfeit and unapproved products
Demand for semaglutide has drawn fakes. On December 5, 2025 the FDA warned that it had seized dozens of units of counterfeit Ozempic 1 mg injection found in the legitimate U.S. supply chain, labeled with lot number PAR1229 (also an authentic lot number); the fakes can be told apart by where the “EXP/LOT” text sits on the pen label. The FDA also warns that compounded and other unapproved GLP-1 products are not reviewed for safety, effectiveness or quality before they are sold. As of May 31, 2026 it had received 990 adverse-event reports linked to compounded semaglutide, and it has reported dosing errors with compounded injections, some leading to hospitalization.
What happens when people stop
Semaglutide works only while it is taken. In the STEP 1 extension, people who stopped semaglutide 2.4 mg and the lifestyle program after 68 weeks regained about two thirds of the weight they had lost within one year, and most heart and metabolic improvements drifted back toward where they started. That is true whichever brand name is on the pen, so a long-term plan matters before starting. Our guide to keeping weight off after a GLP-1 covers the options.
How to talk to your clinician about it
A good conversation, step by step
- Bring your numbersHeight, weight, waist, blood pressure and recent labs. The BMI calculator gives you a starting point.
- Share your full historyThyroid cancer in the family, pancreatitis, gallbladder problems, eye disease, kidney disease and pregnancy plans all matter.
- Ask about the labelAsk which product is approved for your situation and why a clinician might choose one over another.
- Check coverage firstCall your plan about Ozempic and Wegovy, and ask what prior authorization needs.
- Plan the long termAgree on nutrition, protein, strength training and what happens if you stop.
Our BMI calculator and Find My Options tool can help you organize your questions. If you are looking for a clinician who focuses on weight, see obesity medicine specialists or our medical weight loss guide. For every injectable option in one place, go back to weight-loss injections; to protect muscle while losing weight on any GLP-1, read muscle loss on GLP-1s.
Alternatives with a weight-management label
Several medicines are FDA approved specifically for chronic weight management: Wegovy (semaglutide), Zepbound (tirzepatide), Foundayo (orforglipron, a daily pill), Saxenda (liraglutide), and older pills such as Qsymia and Contrave. Each has its own label, trials and risks. Our weight-loss medications hub lists them with their FDA status badges, and Wegovy vs Zepbound compares the two best-known shots. Lifestyle changes remain the base of every plan: see how to lose weight.
Related guides
Weight-Loss Injections: GLP-1 and dual-agonist shots explainedWeight-loss injections explained: which shots are FDA approved for weight vs diabetes, weekly vs daily, using…
Compounded Semaglutide and Tirzepatide: what FDA says and the risksCompounded semaglutide and tirzepatide explained: not FDA approved, the dated shortage history, FDA safety reports, counterfeit…
GLP-1 Side Effects: common, serious and how they are managedGLP-1 side effects from the FDA labels: common digestive effects by brand, serious risks, the thyroid…
Stopping a GLP-1: regain, what trials show and keeping resultsWhat happens when you stop a GLP-1: STEP 1 extension, STEP 4, SURMOUNT-4 and BMJ meta-analysis…Tools for this topic
Latest research
How to Read a Weight-Loss Study Headline in 5 StepsFive questions to ask before believing a weight-loss headline: who was studied, how many, how long,…
What’s Coming in 2027: Weight-Loss Treatments Awaiting FDA DecisionsWeight-loss treatments awaiting FDA decisions in 2027: CagriSema, retatrutide, survodutide, MariTide and more, with filing dates,…
Fake and Counterfeit Weight-Loss Drugs: How to Spot ThemCounterfeit Ozempic has reached U.S. pharmacies three times. The FDA alerts, what online test buys found,…Questions to ask a professional
- Which semaglutide product, if any, is approved for my situation, and why?
- Do I have any history, such as thyroid cancer in my family, pancreatitis or gallbladder disease, that rules it out?
- Will my insurance cover Ozempic or Wegovy for me, and what does prior authorization need?
- How should my other medicines, especially insulin or sulfonylureas, change if I start?
- What is our plan for protein, strength training and the long term if I stop?
Frequently asked questions
Is Ozempic FDA approved for weight loss?
No. Ozempic is approved for adults with type 2 diabetes, to improve blood sugar and to lower heart and kidney risks. The semaglutide product approved for weight management is Wegovy.
Can a doctor prescribe Ozempic for weight loss?
The FDA says providers generally may prescribe an approved drug for an unapproved use when they judge it medically appropriate. That is called off-label use. The FDA has not reviewed Ozempic for weight, and insurance often will not cover it for that purpose.
Is Ozempic the same as Wegovy?
Both contain semaglutide and share the same boxed warning, but they are separate products with different approvals, pens and doses. Wegovy is studied and labeled for weight; Ozempic for type 2 diabetes.
How much weight do people lose on Ozempic?
In the label's 30-week trial in adults with type 2 diabetes, average weight change was -3.8 kg on 0.5 mg and -4.7 kg on 1 mg, versus -1.2 kg on placebo. Results vary from person to person, and these trials were designed to test blood sugar.
Why would someone get Ozempic instead of Wegovy?
Usually because they have type 2 diabetes, which is what Ozempic is approved for. For weight management without diabetes, Wegovy is the semaglutide product with that indication. The choice belongs to you and your prescriber.
Does insurance cover Ozempic for weight loss?
Plans generally cover medicines for the uses on their label, often with prior authorization, so coverage of Ozempic without a type 2 diabetes diagnosis is uncommon. Check your own plan's formulary and rules.
What does Ozempic cost without insurance?
At NovoCare Pharmacy (checked 2026-10-06), new patients pay $199 a month for two fills of 0.25 or 0.5 mg; after that $349 a month for 0.25, 0.5 or 1 mg and $499 for 2 mg. Prices can change.
Are compounded "Ozempic" or semaglutide products the same?
No. Compounded semaglutide is not FDA approved and is not reviewed for safety, effectiveness or quality. The FDA has received hundreds of adverse-event reports and has warned about dosing errors and counterfeit Ozempic.
What happens if I stop semaglutide?
In the STEP 1 extension, people regained about two thirds of their lost weight within a year after stopping. Talk with your prescriber before stopping and plan for the long term.
References
- OZEMPIC (semaglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- Understanding Unapproved Use of Approved Drugs “Off Label”. U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
- Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. doi:10.1111/dom.14725 · PMID 35441470 (accessed October 7, 2026) Randomized trial
- Ozempic online pharmacy: self-pay prices and savings. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
- FDA warns consumers not to use counterfeit Ozempic found in U.S. drug supply chain. U.S. Food and Drug Administration, 2025. (accessed October 7, 2026) Government page
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.